Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

QIAstat-Dx hits the market
July 2019
SHARING OPTIONS:

GERMANTOWN, Md. & HILDEN, Germany—The second quarter of 2019 saw the U.S. launch of QIAGEN N.V.'s QIAstat-Dx syndromic testing system following 510(k) clearance by the FDA and the multiplex QIAstat-Dx Respiratory Panel for simultaneous qualitative detection and identification of more than 20 respiratory viral and bacterial pathogens. The company estimates that the respiratory infections space has an addressable market of roughly 1.5 million tests annually in the United States, and plans to launch a gastrointestinal panel as well later this year.
 
“QIAstat-Dx delivers the precision of molecular testing to identify hard-to-diagnose respiratory infections, which sicken millions of U.S. patients each year and kill tens of thousands. We are pleased to roll out the QIAstat-Dx Respiratory Panel for healthcare providers as they begin to prepare for the 2019-20 flu season,” said Thierry Bernard, QIAGEN's senior vice president and head of molecular diagnostics.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.